Request Sample

Global PARP Inhibitor Biomarkers Market

Oct. 5, 2019

Global PARP Inhibitor Biomarkers Market, By Product and Service Type (Product Type, (Kits, Assays), Service Type, (BRCA 1 & 2 Testing, HRD Testing, HRR Testing, Others), By Application (Breast Cancer, Ovarian Cancer, Others (Prostate, Pancreatic, etc), By Region (North America, Latin America, Europe, Asia-Pacific, Middle East and Africa) - Global Forecast, 2020-2025.

Report Code :FMR627      
Pages :199 Pages
Format :   PPT Format   PDF Format

The global PARP inhibitor biomarkers market was valued at US$ xx million in the year 2019. This market is estimated to be valued at US$ xx million in the year 2020, and is expected to reach US$ xx million by the year 2025, with an estimated CAGR of xx% during the forecast period (2020-2025). PARP are poly (adenosine diphosphate [ADP] ribose) polymerase. It is a bunch of 17 enzymes that integrate various (poly) components of ADP ribose in a trammel and transmit them to the proteins. Poly (ADP-ribose) polymerase (PARP) inhibitor performs a major role in the overhaul of single-strand DNA. The double-strand DNA breaks would generally be restored by the procedure of homologous recombination restoration (HRR), which is a tricky procedure and contains various proteins, notably BRCA1 and BRCA2 which are also called as biomarkers of PARP inhibitors.

Table 1. Global PARP Inhibitor Biomarkers Market Synopsis

Parameters

Description

Market Value (US$ Mn) for the Period

2018-2025

Base Year

2019

Forecast Period

2020-2025

Market Segmentation (By Product and Service Type)

Product Type, (Kits, Assays), Service Type, (BRCA 1 & 2 Testing, HRD Testing, HRR Testing, Others)

Market Segmentation (By Application)

Breast Cancer, Ovarian Cancer, Others (Prostate, Pancreatic, etc.)

Regions Covered

North America, Latin America, Europe, Asia-Pacific, Middle East and Africa

Key Players Coverage

NeoGenomics Laboratories, Inc., Myriad Genetics, Inc., Invitae Corporation, F. Hoffmann-La Roche AG, and BPS Bioscience, Inc., among others.

Key Insights

  • Latest Updates
  • Analyst Views
  • Future Outlook of the Market

Market Dynamics

Surging number of oncology indications, including rising breast cancer, colorectal cancer, gastric cancer, ovarian cancer, malignant melanoma and non-small-cell lung cancer contributes to the growth of the global PARP inhibitor biomarkers market. For instance, as per the World Health Organization’s report of 2018, cancer is the secondary leading reason behind morbidity and mortality globally and was accountable for a predicted 9.6 million mortalities in 2018. Likewise, as per the same history, nearly 1 in 6 mortality takes place because of cancer worldwide.

However, high starting cost of PARP inhibitor biomarker test kits is expected to restrain the global PARP inhibitor biomarkers market growth. For instance, according to the data presented by American Society of Clinical Oncology (ASCO) 2018, PARP inhibitors would require at least a 50% reduction in cost to become cost-neutral with Anti–vascular endothelial growth factor (VEGF) therapy.

Figure 1. PARP Inhibitor Biomarkers Market Scenario Forecast (Likely, Conservative, and Optimistic Scenario), 2019 and 2025 (US$ Mn)

Note: The above figure is shown for illustrative purposes only, the actual data may vary and will be incorporated in the report.

North America is predicted to hold a dominant share in the global market in 2019 owing to rising product approvals by the government. For instance, in July 2019, Foundation Medicine, Inc., a subsidiary of F. Hoffmann-La Roche AG, got acceptance from the U.S. Food and Drug Administration (FDA) for Foundation One CDx to be used as a compatriot diagnostic for LYNPARZA (Olaparib) for first line maintenance therapy in BRCA-mutated fostered ovarian cancer. Moreover, in October 2019, Myriad Genetics, Inc. has got the U.S. Food and Drug Administration’s acceptance for myChoice CDx as a companion diagnostic to diagnose women with advanced ovarian cancer who are participants for Zejula (niraparib) in the late-line treatment setting.

Figure 2. Regional Analysis

Note: The above figure is shown for illustrative purposes only, the actual data may vary and will be incorporated in the report.

Competitve Landscape

Key players in the global PARP inhibitor biomarkers market include: NeoGenomics Laboratories, Inc., Myriad Genetics, Inc., Invitae Corporation, F. Hoffmann-La Roche AG, and BPS Bioscience, Inc., among others.

The various approaches adopted by the key market players are new product launches and mergers and acquisition to establish a significant position in the market.  For instance, in June 2017, Ambry Genetics (Ambry), a clinical genetics-testing lab, released two paired (simultaneous germline and somatic) genetic tests namely TumorNext-HRD and TumorNext-Lynch. TumorNext-HRD is the first test to offer concurrent genomic details about both somatic and hereditary cancer and validates acceptability for selected treatment options.

Additionally, in June 2018, F. Hoffmann-La Roche AG and Foundation Medicine, Inc. signed a collaboration agreement to expedite possibility of overall genomic profiling in oncology. The mergers targeted on driving pervasiveness of Foundation Medicine’s effective quality comprehensive genomic profiling (CGP) testing and creative data services with the motive to acquire Roche’s vision [1] of personalized healthcare system. These collaborations allow companies to expand their product portfolio and also to expand their footprints in different regions and countries.

Figure 3. Market Share of Key Players, 2019

Note: The above figure is shown for illustrative purposes only, the actual data may vary and will be incorporated in the report.

By Product and Service Type

  • Product Type
    • Kits
    • Assays
  • Service Type
    • BRCA 1 & 2 Testing
    • HRD Testing
    • HRR Testing
    • Others

By Application

  • Breast Cancer
  • Ovarian Cancer
  • Others (Prostate, Pancreatic, etc.)

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa
rm
Kindly fill the below form and we will contact you within 24 hours
I have read and accept Privacy Policy

Confidentiality

We respect your privacy rights and safeguard your personal information. We prevent the disclosure of personal information to third parties.

Note: This report provides in-depth analysis of the global PARP inhibitor biomarkers market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020-2025), considering 2019, as the base year.

  • What are the trends adopted by key players in the global PARP inhibitor biomarkers market?
  • What key factors are expected to increase the demand for PARP inhibitor biomarkers market during the forecast period 2020-2025?
  • What are the major challenges inhibiting the growth of the global PARP inhibitor biomarkers market?
  • What is the total market value (US$ Mn) generated in global PARP inhibitor biomarkers market by product and services type in 2019 and what are the forecasts by 2025?
  • Which application is expected to dominate the PARP inhibitor biomarkers market in the coming years?
  • What was the total revenue generated by the global PARP inhibitor biomarkers market across different regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa) in 2019, along with CAGR (%) for the period (2020-2025)?
  • Who are the key players contributing to the growth of the global PARP inhibitor biomarkers market, and what are the new strategies adopted by them to retain a market share in the industry?
  • What is the competitive strength of the key players in the PARP inhibitor biomarkers market?
  • What are the major outcomes derived from the Porter’s five forces?
  • What new products are going to be approved or launched in the coming years which may have huge impact on the market?
  • What insights are derived through the analysis of key players on following parameters: company overview, financial performance, product portfolio, geographical presence, key highlights, and strategies?

Latest Reports

Global Sleep Testing Services Market

Global Sleep Testing Services Market, By Test Type (Home Sleep Testing and In-lab Sleep Testing (Electroencephalogram, Full Polysomnography, CPAP/BiPAP …

Read More

Global Sarcoma Biopsy Market

Global Sarcoma Biopsy Market, By Product Type (Reusable Device, Disposable Devices), By End User (Hospitals, Ambulatory Surgical Centers, Diagnostic …

Read More

Global Rheumatoid Arthritis Diagnostic Tests Market

Global Rheumatoid Arthritis Diagnostic Tests Market, By Test Type (serology tests (erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), anti-cyclic …

Read More

Global PARP Inhibitor Biomarkers Market

Global PARP Inhibitor Biomarkers Market, By Product and Service Type (Product Type, (Kits, Assays), Service Type, (BRCA 1 & …

Read More

North America Outbound Medical Tourism Services Market

North America Outbound Medical Tourism Services Market, By Treatment Type (Cardiovascular Treatment, Cosmetic Surgery Treatment, Dental Treatment, Weight Loss …

Read More

Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market

Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market, By Product Type (Instruments and Reagents and Kits ), By …

Read More

Global Bilirubin Blood Test Market

Global Bilirubin Blood Test Market, By Test Type (Direct/Conjugated Bilirubin Test, Indirect/Unconjugated Bilirubin Test, Total Serum Bilirubin (TSB), By …

Read More

Global In Vitro Toxicity Testing Market

Global In Vitro Toxicity Testing Market, By Product & Service (Consumables, Assays (Bacterial Toxicity Assays, Enzyme Toxicity Assays, Cell-based …

Read More
Validation error occured. Please enter the fields and submit it again.